JNJ vs ABBV
By Alex · Tickerpine
Johnson & Johnson vs AbbVie Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | JNJ | ABBV |
|---|---|---|
| Price | $271.22 | $264.34 |
| Market cap | $653.61B | $467.12B |
| P/E ratio | 31.5 | 74.5 |
| ROE | 25.74% | — |
| Profit margin | 21.48% | 9.80% |
| Revenue growth | 6.60% | 10.20% |
| Dividend yield | 1.98% | 2.62% |
| Beta | 0.23 | 0.28 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
JNJ vs ABBV in plain English
- JNJ is the bigger company — about 1.4× the market cap of ABBV.
- JNJ is cheaper on earnings (P/E 31.5 vs 74.5).
- ABBV is growing revenue faster (10% vs 7%).
- ABBV has the higher dividend yield (2.62% vs 1.98%).
How would $1,000 have done in each?
JNJ return calculator
See what $1,000 in Johnson & Johnson would be worth today.
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.